Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Metastatic melanoma, Unresectable melanoma Age: Adult |
Dose: Intravenous – 2 mg/kg or 200 mg Frequency: once every 3 weeks Duration: until disease progression or unacceptable toxicity Note: Administer via infusion over 30 minutes; dose modification, interruption, or discontinuation (based on severity) may be required if immune- or infusion-related reactions occur. |
|
Indication: Locally advanced non-small cell lung carcinoma, Metastatic non-small cell lung carcinoma Age: Adult Condition: Patients who have been treated with chemotherapy |
Dose: Intravenous – 2 mg/kg Frequency: once every 3 weeks Duration: until disease progression or unacceptable toxicity Note: Administer via infusion over 30 minutes; dose modification, interruption, or discontinuation (based on severity) may be required if immune- or infusion-related reactions occur. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Classical Hodgkin Lymphoma or Melanoma Age: 12 years and older |
Dose: Intravenous – 2 mg/kg Frequency: every 3 weeks Note: Max Dose: 200 mg |
|
Indication: cHL, MSI-H or dMMR Cancer, or MCC Age: Pediatric |
Dose: Intravenous – 2 mg/kg Frequency: every 3 weeks Note: Max Dose: 200 mg |
Administration
- Given as IV infusion over 30 minutes
- Must be diluted before use
Side Effect
- Significant Colitis
- hepatitis
- nephritis
- severe endocrinopathies (eg diabetic ketoacidosis
- diabetes mellitus
- hypo- or hyperthyroidism
- hypophysitis
- severe infusion-related reactions (eg hypersensitivity
- anaphylaxis)
- hepatic veno-occlusive disease in patients with classical Hodgkin lymphoma undergoing allogeneic HSCT
- Anaemia
- Abdominal pain
- constipation
- diarrhoea
- dry mouth
- nausea
- vomiting
- Fatigue
- asthenia
- oedema
- chills
- pyrexia
- influenza-like illness
- Increased AST/ALT
- alkaline phosphatase
- and blood creatinine
- Decreased appetite
- Musculoskeletal pain
- arthralgia
- arthritis
- myositis
- pain in extremity
- Dizziness
- dysgeusia
- headache
- thoracic and mediastinal disorders Cough
- dyspnoea
- Dry skin
- erythema
- pruritus
- rash
- vitiligo
- Pneumonitis
- Stevens-Johnson syndrome
- toxic epidermal necrolysis
- Graft-versus-host-disease and severe sinusoidal obstructive syndrome (in patients with history of HSCT)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Systemic Corticosteroids (Prednisone, Prednisolone, Methylprednisolone, Dexamethasone, Hydrocortisone), Immunosuppressants (Cyclosporine, Tacrolimus, Mycophenolate, Azathioprine)
|
Use before starting therapy may cause interference with pharmacodynamic activity and efficacy
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store vials under refrigeration at 2°C to 8°C.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.